Verrica Pharmaceuticals Inc. (VRCA)
$3.83+6.98%Close
SELLCRISIS · day 9
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $41M
- Beta
- 1.61
- P/E (TTM)
- -2.20
- Short % float
- 2.90%
- Days to cover
- 4.1
- SI change
- -3.2%
- 1W
- -7.49%
- 1M
- -16.38%
- vs SPY 1W
- -7.35%
- vs SPY 1M
- -18.88%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 2
- VALUE
- 4
- GROWTH
- 40
- GARP
- 4
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-266.7%
REV YoY-
ROE-444.4%
EPS YoY-
ROA-86.6%
GROSS86
OP-93
NET-103
[VALUATION]
P/E TTM-2.20
P/E FWD-
SECTOR PE20.48
INDUSTRY PE13.99
P/B18.95
P/FCF-
EV/EBITDA-2.11
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E42.02
ALTMAN Z-
CURR RATIO1.45
ND/EBITDA-
BETA1.61
Company news
FAQ
- What is LOPJLB’s current signal on VRCA?
- LOPJLB’s latest quantitative signal on Verrica Pharmaceuticals Inc. (VRCA) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is VRCA in?
- Verrica Pharmaceuticals Inc. (VRCA) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Verrica Pharmaceuticals Inc. (VRCA) do?
- Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the …